With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Novo Nordisk A/S Dữ liệu về giá theo thời gian thực
The current price of Novo Nordisk A/S in the market is 1.090.117,13 ₫, with a 24-hour trading volume of 25,33T ₫. The asset's market cap is 4,83P ₫, after moving 6.88% in the last day.
Tokenized Novo Nordisk A/S is trading at 1.103.837,06 ₫, with a tokenized market cap of 90,46B ₫ and a 24-hour trading volume of 22,9B ₫. The tokenized asset has moved 8.57% in the past 24 hours.